190 related articles for article (PubMed ID: 27659013)
1. Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.
Latagliata R; Stagno F; Annunziata M; Abruzzese E; Iurlo A; Guarini A; Fava C; Gozzini A; Bonifacio M; Sorà F; Leonetti Crescenzi S; Bocchia M; Crugnola M; Castagnetti F; Capodanno I; Galimberti S; Feo C; Porrini R; Pregno P; Rizzo M; Antolino A; Mauro E; Sgherza N; Luciano L; Tiribelli M; Russo Rossi A; Trawinska M; Vigneri P; Breccia M; Rosti G; Alimena G
Neoplasia; 2016 Sep; 18(9):536-40. PubMed ID: 27659013
[TBL] [Abstract][Full Text] [Related]
2. Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.
Markovic U; Bulla A; Leotta S; Stella S; Consoli ML; TambÈ L; Conticello C; DI Raimondo F; Stagno F
Anticancer Res; 2020 Sep; 40(9):5313-5317. PubMed ID: 32878823
[TBL] [Abstract][Full Text] [Related]
3. Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.
Stagno F; Breccia M; Annunziata M; Trawinska MM; Iurlo A; Sgherza N; Fava C; Gozzini A; Luciano L; Carmosino I; Bonifacio M; Sorà F; Leonetti Crescenzi S; Crugnola M; Gugliotta G; Galimberti S; Bucelli C; Colafigli G; Feo C; Tiribelli M; Mauro E; Russo Rossi A; Guarini A; Abruzzese E; Rosti G; Di Raimondo F; Latagliata R
Acta Oncol; 2021 Nov; 60(11):1527-1533. PubMed ID: 34499575
[TBL] [Abstract][Full Text] [Related]
4. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
Naqvi K; Jabbour E; Skinner J; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
Cancer; 2018 Jul; 124(13):2740-2747. PubMed ID: 29723397
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
Naqvi K; Jabbour E; Skinner J; Anderson K; Dellasala S; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
Cancer; 2020 Jan; 126(1):67-75. PubMed ID: 31553487
[TBL] [Abstract][Full Text] [Related]
6. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
[TBL] [Abstract][Full Text] [Related]
7. Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.
Murai K; Yamaguchi K; Ito S; Miyagishima T; Shindo M; Wakasa K; Inomata M; Nagashima T; Kondo T; Fujimoto N; Yamamoto S; Yonezumi M; Oyake T; Kowata S; Tsukushi Y; Mine T; Meguro K; Ikeda K; Watanabe R; Saito S; Sato S; Tajima K; Chou T; Kubo K; Oba K; Sakamoto J; Ishida Y;
Eur J Haematol; 2018 Jan; 100(1):27-35. PubMed ID: 28895203
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
12. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.
Breccia M; Latagliata R; Stagno F; Luciano L; Gozzini A; Castagnetti F; Fava C; Cavazzini F; Annunziata M; Russo Rossi A; Pregno P; Abruzzese E; Vigneri P; Rege-Cambrin G; Sica S; Pane F; Santini V; Specchia G; Rosti G; Alimena G
Haematologica; 2011 Oct; 96(10):1457-61. PubMed ID: 21685471
[TBL] [Abstract][Full Text] [Related]
13. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia: Second-line drugs of choice.
Gambacorti-Passerini C; Aroldi A; Cordani N; Piazza R
Am J Hematol; 2016 Jan; 91(1):67-75. PubMed ID: 26588811
[TBL] [Abstract][Full Text] [Related]
15. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
Iurlo A; Galimberti S; Abruzzese E; Annunziata M; Bonifacio M; Latagliata R; Pregno P; Ferrero D; Sorà F; Orlandi EM; Fava C; Cattaneo D; Bucelli C; Binotto G; Pungolino E; Tiribelli M; Gozzini A; Gugliotta G; Castagnetti F; Stagno F; Rege-Cambrin G; Martino B; Luciano L; Breccia M; Sica S; Bocchia M; Pane F; Saglio G; Rosti G; Specchia G; Cortelezzi A; Baccarani M
Ann Hematol; 2018 Jan; 97(1):95-100. PubMed ID: 28971265
[TBL] [Abstract][Full Text] [Related]
16. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results.
Gener-Ricos G; Haddad FG; Sasaki K; Issa GC; Skinner J; Masarova L; Borthakur G; Alvarado Y; Garcia-Manero G; Jabbour E; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):742-748. PubMed ID: 37308342
[TBL] [Abstract][Full Text] [Related]
18. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
[TBL] [Abstract][Full Text] [Related]
19. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
[TBL] [Abstract][Full Text] [Related]
20. Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib.
Janjetovic S; Asemissen AM; Dicker F; Binder M; Dierlamm J; Bokemeyer C; Schafhausen P
Tumori; 2019 Dec; 105(6):NP8-NP11. PubMed ID: 30935343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]